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Abstract
Adoptive transfer of T cells transduced with Chimeric Antigen Receptors (CAR) are now FDA-approved for the treatment
of B-cell malignancies. Yet, the functionality of the endogenous TCR in CART cells has not been fully assessed. Here, we
demonstrate that CART cells progressively upregulate Fas, FasL, DR5 and TRAIL, which result in their programmed cell
death, independently of antigen-mediated TCR or CAR activation. CART cell apoptosis occurs even when the CAR
contains a single (co-)activatory domain such as CD3ζ, CD28 or 4-1BB. Importantly, the dominant role of the
Fas and DR5 pathways in CART cell apoptosis is demonstrated by the significant rescue of CART cells upon
in vivo blockade by combined Fas-Fc and DR5-Fc recombinant proteins. These observations are of crucial
importance for the long-term persistence of CART cells and for the development of new applications including the
combined TCR and CAR activation against solid tumors.
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Introduction
Adoptive T cell immunotherapies involving CART cells
show impressive clinical responses in advanced cancer
[1–5]. Two CART cell products were recently
FDA-approved for the treatment of B cell malignancies,
and ongoing research aims to extend this approach for the
treatment of acute myeloid leukemia [6], multiple mye-
loma [7] and solid tumors [8, 9]. CART cell therapy ap-
plied to solid tumors is facing additional challenges, such
as multiple mechanisms of tumor escape, including the
highly immunosuppressive tumor microenvironment, and
the selection of tumor-specific antigens causing minimal
off- and on-target toxicity. Around forty clinical trials are
currently open against a large variety of solid malignan-
cies. In contrast to hematological malignancies, a few
completed clinical studies showed a good safety profile,
but unfortunately, no signs of clinical activity [10]. With
the aim to enhance the effectiveness of CART cell therapy,
we and others have evaluated the transduction of a CAR
into tumor antigen-specific T cells, so as to attack the
tumor via combined TCR and CAR activation. However,
all in vivo pre-clinical studies have failed so far to demon-
strate a combined TCR/CAR activation associated with
synergistic antitumor effect [11–14]. In this regard, we
have evaluated the functionality of the resident TCR in
CART cells, either by using a bacterial infection model or
in therapeutic tumor settings. Unexpectedly, we found
that independently of TCR activation, CART cells
undergo programmed cell death (PCD) associated
with the up regulation of Fas, FasL, DR5 and TRAIL
expression, resembling the process of Activation In-
duced Cell Death (AICD), which occurs upon exces-
sive T cell stimulation or during the T cell
contraction phase.
Results and discussion
H-2Kb/OVA specific OT-1 T cells were transduced with
a human-specific HER2-CAR bearing different combina-
tions of co-stimulatory signaling domains (Fig. 1a),
which were validated in vitro (Additional file 1: Figure S1).
All CAR configurations were functional except the
HER2-CAR with single domain CD28 or 4-1BB, as they
lacked the CD3ζ domain. First, we assessed the CART cell
response upon in vivo engagement of the resident TCR by
cognate antigen on microbial infection. To this aim,
HER2-CAR OT-1 T cells were transferred into recipient
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mice, which were subsequently infected with recombinant
Listeria monocytogenes bacterium genetically modified to
express the chicken ovalbumin sequence (OVA133–387),
referred thereafter as rLm-OVA (Fig. 1b) [15]. We found
that all CART cells, regardless of the CAR construct, had
almost completely disappeared at the peak of infection on
day 7, in contrast to the large expansion of control-
transduced (BFP) T cells (Fig. 1c). Strikingly, even the
single co-stimulatory domains CD28 and/or 4-1BB were
able to mediate CART cell death following stimulation of
the resident TCR, although the CAR itself lacking the
CD3ζ domain was not functional (Additional file 1:
Figure S1). Longitudinal monitoring of the T cell re-
sponse at earlier time points showed that HER2-CART
cells bearing the co-stimulatory domains CD3ζ and
41BB domains (BBz) expanded efficiently until day 5
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Fig. 1 After their initial expansion, HER2-specific CART cells undergo apoptosis. a Schemes of tested HER2-CAR configurations. b Schematic
representation of the experimental protocol c Frequencies of BFP or HER2-CART cells bearing various CAR co-stimulatory domains out of
total live cells in the spleen at day 7 post rLm-OVA infection. d Representative FACS plots of CART cell frequencies of CART cells at day
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Percentage of HER2- positive OT-1 T cells at day 7 post infection with rLm-OVA in the spleen and liver of mice that received either the control hIgG1
or both Fas-Fc and DR5-Fc. Statistical analysis by One-way ANOVA (c and e) and by T-test (g), n = 4 (c-e) or 5 (g) mice per group. * P < 0.05, ** P < 0.01,
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post-infection, then declined by day 6 and had mostly
disappeared on day 7 (Fig. 1d). The dramatic loss of
CART cells was seen in blood, spleen, mesenteric
lymph nodes and liver (Additional file 1: Figure S2),
and correlated with the up-regulation of Fas, FasL,
DR5, TRAIL and Annexin V on days 6 and 7, suggesting
their possible deletion via Fas and DR5-mediated AICD
(Fig. 1e). The upregulation of cell death markers was seen
with all configurations of CAR co-stimulatory do-
mains, as seen by Fas, FasL, DR5, TRAIL and
Annexin V up-regulation, albeit with slightly different
amplitudes (Additional file 1: Figure S3). The Fas and DR5
signaling pathways were necessary for TCR-induced
CART cell apoptosis, as shown by the significant rescue of
CART cells in spleen and liver upon systemic treatment
with the cocktail of recombinant Fas-Fc and DR5-Fc pro-
teins (Fig. 1f). To further assess if TCR triggering was re-
quired for CART cell apoptosis, we monitored the survival
of 5 × 106 HER2-CARBBz or BFP OT-1 T cells transferred
in naïve B6 mice, which were lymphodepleted with cyclo-
phosphamide to allow engraftment of T cells in the ab-
sence of antigen stimulation. Strikingly, CAR OT-1 T cells
were also prone to PCD in the absence of the OVA anti-
gen and CAR activation, as seen by their reduced frequen-
cies at day 14 post CART cell transfer associated with the
upregulation of Fas, FasL, and Annexin V (Fig. 2). Of note,
DR5 and TRAIL were not upregulated on CART cells in
the absence of TCR triggering, suggesting that additional
death signals might be induced upon concomitant TCR
and/or CAR activation. The susceptibility of CART cells
to PCD was not peculiar to the HER2-CAR, as OT-1 T
cells transduced with a CEA-CAR also upregulated Fas
and FasL and underwent subsequent cell death upon
rLm-OVA infection in the absence of CAR activation
(Additional file 1: Figure S4). In view of the clinical suc-
cess of CART cells in cancer immunotherapy, we evalu-
ated whether CART cell susceptibility to apoptosis would
compromise their antitumor activity against tumors ex-
pressing the TCR and/or CAR antigen (Fig. 3a and e).
When 5 × 106 BFP or HER2-CAR OT-1 T cells were
transferred in cyclophosphamide pre-conditioned mice
bearing B16-OVA tumors, the TCR-mediated antitumor
effects were similar for the first three weeks post tumor
graft (Fig. 3b). However, a significant upregulation of cell
death markers was already detected at day 7 post ACT on
spleen (Fig. 3c) and tumor-infiltrating CART cells (data
not shown). As a consequence, frequencies and tumor
control of CART cells progressively decreased, and on day
28 post tumor graft, tumor volumes were significantly lar-
ger than in mice transferred with control BFP-OT-1 cells,
which was associated with decreased tumor infiltration of
OT-1 CART cells (Fig. 3d). Importantly, when engaging
OT-1 CART cells via both the OT-1 TCR and the
HER2-CAR against B16-OVA/HER2 tumors (Fig. 3e),
there was no sign of additive antitumor effect, while the
HER2-CAR was able to mediate significant antitumor ef-
fect when transduced in naïve CD8 T cells bearing poly-
clonal TCRs (Fig. 3f). Similar to what was observed in the
B16-OVA model, Fas, FasL, DR5 and TRAIL were signifi-
cantly upregulated, and to a similar extent on spleen OT-1
and polyclonal CD8 CART cells on day 9 post ACT
(Fig. 3g). Accordingly, on day 28 post tumor graft, tumor
volumes were significantly larger in mice transferred with
CART cells, which correlated with reduced tumor infiltra-
tion of CART cells, whether the CAR was transduced in
OT-1 or polyclonal CD8 T cells (Fig. 3h).
Overall, we found that CART cells are intrinsically
prone to Fas- and DR5-mediated programmed cell
death, as shown by their partial rescue upon blockade of
these death signaling pathways. The progressive loss of
CART cells in tumor bearing mice, did not hinder TCR
or CAR-mediated antitumor effects, but prevented their
long-term therapeutic effects, as well as the additive an-
titumor activity via combined TCR and CAR tumor tar-
geting. Strikingly, the susceptibility of CART cells to cell
death occurred with all tested CAR configurations even
those with a single CD28 and/or 4-1BB CAR domain.
These results were particularly unexpected as CD28 and
4-1BB pathways have been rather associated with T cell
persistence and resistance to exhaustion [16, 17]. How-
ever, depending on the context, both co-stimulatory do-
mains might also be involved either directly or indirectly
in the induction of T cell apoptosis [18, 19]. We can
speculate that the efficient transduction of CARs leads
to a supra-physiological expression levels of CD3ζ,
CD28 or 4-1BB domains, as compared to their endogen-
ous expression, which may result in some tonic signaling
upon TCR/MHC cognate interaction. The slow kinetic
of CART cell death shown in the homeostatic or tumor
settings, versus the fast CART cell loss in the rLm-OVA
model, suggests that the intensity of TCR triggering and
the inflammatory milieu are playing a role. For instance,
CD28 has been shown to recruit Lck [20], which could
cooperate and increase TCR signaling resulting in in-
creased NF-κB and induction of Fas/FasL expression.
While the role of enhanced CD28 signaling seems rather
indirect, 4-1BB signaling has been directly associated
with Fas/FasL-dependent apoptosis of T cells in defined
contexts [19], in particular, in the presence of high
CD19-CAR expression containing a 4-1BB domain [18].
Therefore, it will be important to determine whether
high expression levels of CAR-associated co-stimulatory
domains generate a weak but constitutive activation sig-
nal in T cells, which may lead to a low noise level of
NFκB activation sufficient to induce Fas/FasL upregula-
tion. Moreover, the constitutive resident TCR engage-
ment by low affinity self MHC/peptide ligands [21], may
contribute to an aberrant CART cell activation.
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Interestingly, another study has recently reported
TCR-mediated CART cell apoptosis [22], using an in
vivo model involving the rejection of CD19-CART cells
when expressing a TCR specific for the HY-male antigen.
Consistent with our study in acute infection models, de-
letion of female HY-specific CD19-CART cells was ob-
served upon their transfer in HY+ male hosts.
Intriguingly, T cell attrition in that model was more se-
vere in CD8 than in CD4 T cells. As a consequence,
CD8 CART cells failed to control B cell lymphoma tu-
mors, while CD4 T cells retained antitumor effect but
were ultimately also deleted. As the TCR antigen was
presented by all male cells, the loss of HY-specific
CD19-CART cells was likely more dramatic than in our
study in which TCR triggering was restricted to
OVA-expressing tumor cells, which likely allowed longer
survival or CART cells and tumor inhibition. Another
supportive indirect evidence of TCR dysfunction in
CART cells was reported recently in clinical trials involv-
ing the transfer of allogeneic CD19-CART cells in
pediatric leukemic patients [23, 24]. Strikingly, a signifi-
cant decreased GvHD was observed when allogeneic
donor cells were expressing a CAR. The same authors
confirmed a diminished GvHD in a subsequent
pre-clinical study, and showed that alloreactive CART
cells were characterized by enhanced stimulation associ-
ated with progressive loss of effector function, prolifera-
tion and clonal deletion [25]. In view of these results, we
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hypothesize that the persistence of CART cells bearing
an alloreactive TCR was decreased due to
alloantigen-mediated activation and accelerated cell
death, which was instrumental for the decreased GvHD.
In that study, decreased GvHD was selectively associated
with CD28-bearing CAR but not for 4-1BB or first gen-
eration’s CARs. Instead, in our models, the apoptosis of
CART cells took place regardless of the number and type
of co-stimulatory domains, and independently of TCR and
CAR activation. We therefore speculate that the intrinsic
susceptibility of CART cells to programed cell death might
be further enhanced upon TCR and/or CAR activation. Of
note, a recent study has reported that the CRISPR/Cas9-
mediated targeting of the CAR to the TCR locus prevents
CAR tonic signaling and delays CART cell exhaustion,
which results in enhanced tumor rejection [26]. Although
this approach would not allow the combined TCR and
CAR activation, it would be very interesting to see if such
TCR-deficient CART cells would have decreased suscepti-
bility to PCD and therefore better persistence.
Many aspects of CART cell persistence and survival
remain to be studied both in pre-clinical and clinical sit-
uations. However, these recent data including ours have
revealed a so far poorly appreciated susceptibility of
CART cells to PCD. Our study does not challenge the
success of CART cells in cancer patients, but demon-
strates the need to ameliorate the long term persistence
of CART allowing combined TCR and CAR activation,
in particular for the treatment of solid tumors. In this
context, alternative strategies may be developed, which
include the careful control of the dose of CAR
expressed, the CAR gene targeting in the TCR gene
locus, the potential use of CD4 instead of CD8 T cells as
CART cell recipient, or possibly the CART cell intrinsic
blockade of apoptotic pathways.
Methods
Mice
Female mice C57BL/6 J (B6) six to eight weeks old
(Envigo, Gannat, France) were maintained in specific
pathogen-free conditions. All animal experiments were
conducted according to institutional guidelines and
under the authorization VD1605 delivered by the Swiss
veterinary department.
Retroviral constructs
BFP fluorescent protein, HER2 and CEA-specific CARs
were cloned in the MSGV retroviral transfer vector [27]
under the control of the 5′ LTR promoter. For the
HER2-CAR, the plasmid pIG6-4D5, containing the scFv
fragment derived from the human-specific anti-HER2
murine antibody 4D5, was used as template [28] (kind
gift from A. Pluckthun, University of Zurich, Switzerland).
For the CEA-CAR, the scFv MFE23 [29] (kindly provided
by R.H. Begent) was used. The single chain antibody frag-
ment was fused to the CD8α hinge and transmembrane
domains followed by mouse intracellular TCR signaling
endodomains.
Retrovirus preparation
For each retroviral preparation, 8 × 106 Phoenix ECO
cells (ATCC, CRL-3214) were plated in a T150 tissue
culture flask in RPMI medium supplemented with
10% FCS, 10 mM HEPES and 50 U/ml
Penicillin-Streptomycin. On the next day, cells were
transfected with 21 μg of the retroviral construct with
Turbofect transfection reagent (Thermo Fischer Sci-
entific), according to the manufacturer protocol. The
medium was changed daily and collected at 48 h and
72 h post transfection. 48 h and 72 h virus superna-
tants were pooled and sedimented at 22000rcf for 2 h
at 4 °C. Finally, retrovirus pellets were resuspended in
2 ml of full RPMI medium and divided in 8 aliquots
of 250 μl each, which were snap-frozen on dry ice
and stored at − 80 °C.
Mouse CD8 T cells transduction
Spleens from CD45.1xOT1 or CD45.1xP14 transgenic
mice were smashed on a 40 μm cell strainer. CD8 T cells
were purified using the EasySep™ Mouse CD8+ T Cell
Isolation Kit (StemCell) according to the manufacturer
protocol. 0.5 × 106 CD8 T cells were plated in 48well
plates in 0.5 ml of complete RPMI 1640 medium supple-
mented with 10% FCS, antibiotics and 50 IU/ml of re-
combinant human IL-2. Mouse T-cells were activated
with Activator CD3/CD28 Dynabeads (Gibco) at a ratio
of 2 beads per cell. Retroviral infection was conducted at
37 °C for 24 h. Untreated 48well plates were coated for
24 h with 20 μg/ml of recombinant human fibronectin
(See figure on previous page.)
Fig. 3 The susceptibility of CART cells to programmed cell death progressively decreases their anti-tumoral capacity. a Scheme of the experiment
in which mice were engrafted with B16-OVA tumors, conditioned with cyclophosphamide and treated with BFP or HER2-BBz OT-1 CART cells. b
Evolution of tumor volumes over time. c Expression of Fas, FasL, DR5 and TRAIL in BFP or CART cells in the spleen at day 7 post transfer. d Tumor
volume and percentage of BFP or CART cells in total live cells in the tumors at day 21 post transfer. e Scheme of the experiment in which mice
were engrafted with B16-OVA-HER2 tumors, conditioned with cyclophosphamide and treated with BFP or HER2-BBz OT-1 or polyclonal CART cells.
f Evolution of tumor volumes over time. g Expression of Fas, FasL, DR5 and TRAIL in BFP or CART cells in the spleen at day 9 post transfer. h Tumor
volume and percentage of BFP or CART cells in total live cells in the tumors at day 22 post transfer. Statistical analysis by T-test (c, d, h)
and by One-way ANOVA (g, h). Each sample were compared to OT1⋅BFP (g), n = 10 mice per group. * P < 0.05, ** P < 0.01, *** P < 0.001
and **** P < 0.0001
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(Takara Clontech) at 4 °C, followed by PBS 2% BSA for
30 min at RT and finally washed with PBS. One aliquot
of concentrated retroviruses was plated in each
fibronectin-coated 48well plates and centrifuged for
90 min at 2000rcf and 32 °C. Then, 0.5 × 106 of 24 h-acti-
vated CD8 T cells were added on top of the viruses and
spun for 10 min at 400rcf and 32 °C. Medium was
renewed daily and cell density was kept below 2 × 106
cells/ml. On day 3, the medium was supplemented with
10 IU/ml recombinant human IL-2, 10 ng/ml recombin-
ant human IL-7 and 10 ng/ml recombinant human
IL-15. From day 5 post activation, the cells were fed with
only IL-7 and IL-15.
rLm-OVA infection model
BFP or CART cells were harvested and CD3/CD28
Dynabeads were removed. Cells were counted and
washed 3 times in PBS. 0.2 × 106 cells were resuspended
in 200 μl of plain RPMI medium and injected in the
mouse tail vein.
rLm-OVA infection
2000 cfu were injected i.v. in 200 μl of PBS.
Therapeutic tumor model
C57BL/6 mice were engrafted subcutaneously with
4 × 105 B16F10 tumors modified to express the OVA
antigen with or without HER2. Six days later, mice
were lymphodepleted with 100 mg/kg cyclophospha-
mide (Sigma Aldrich, C7397) injected i.p., and homo-
geneous groups were constituted with regard to
tumor volume. T cells (5 × 106) were adoptively trans-
ferred i.v. on the next day. Kinetic of tumor growth
was monitored every two days with an electronic
caliper. CART cell analysis in the spleens was per-
formed as described previously. Tumors were col-
lected and separated from skin. Single cell
suspensions were obtained with the Mouse Tumor
Dissociation Kit (Miltenyi, 130–096-730) according to
the manufacturer protocol.
Sample preparation, flow cytometry staining and acquisition
Spleens were collected at indicated days post rLm-OVA,
and smashed on 40 μm cell strainers to obtain single cell
suspensions. Red blood cells were lysed using a RBC
Lysis Solution (Qiagen). Livers were smashed using a tea
strainer. Large debris were discarded with a low speed
centrifugation. Then, lymphocytes were enriched by
density separation with two phases of 40 and 70%
Percoll (GE Healthcare, GE17–0891-01). Single cell sus-
pension from lymph nodes were obtained by smashing
the organs on a 40 μM strainer. Blood samples were
treated with RBC Lysis solution. Prior to labelling, Fc re-
ceptors were blocked using 2.4G2 supernatant. Cells
were labelled with Zombie Yellow™ Fixable Viability Kit
(Biolegend) to discriminate dead cells. HER2-specific
CARs were labelled with HER2-Fc (Sino Biological) at
5 μg/ml on ice for 20 min and then washed 3 times with
PBS, 2% FCS, 2.5 mM EDTA (facs buffer). Next, cells
were labelled with Brilliant Violet 421 anti-human IgG
Fc Antibody (BioLegend) at 2 μg/ml for 20 min on ice
and washed again 3 times. The CEA-specific CAR was
instead stained with Fluorescein AffiniPure Goat
Anti-Mouse IgG, F(ab’)2 (Jackson ImmunoResearch) at
1 μg/ml on ice for 20 min and then washed 3 times.
After CAR staining, transduced cells were labelled with
CD3-Alexa Fluor 700 at 10 μg/ml (BioLegend, 100,215),
CD8α-PE/TexasRed at 1/500 dilution (Thermo Fischer
Scientific, MCD0817), CD45.1-APC/eFluor 780 at 2 μg/
ml (eBioScience, 47–0453-82), CD45.2-PerCP/Cy5.5 at
2 μg/ml (BioLegend, 109,827), Fas-APC at 2 μg/ml (Bio-
Legend, 152,603) and FasL-Biotin at 5 μg/ml (BioLegend,
106,603). Cells were then washed once and labelled with
Streptavidin-PE/Cy7 at 0.4 μg/ml (BioLegend, 405,206).
Finally, cells were washed again and stained with
Annexin V-PE (BioLegend, 640,907) according to the
manufacturer protocol, and acquired on a BD LSR2 flow
cytometer.
In vitro cytokine release assay for CART cells
0.2 × 106 OT-1 CART cells were plated in flat-bottom
96well plates with either 0.1 × 106 B16, B16-OVA or
B16-HER2 tumor cells. 30 min later, the Monensin and
Brefeldin A-containing reagents Golgi Stop and Golgi
Plug (Becton Dickinson) were added at the final concen-
tration of 1:1000. Cells were further incubated for 4 h
prior to staining for flow cytometry. Cells were labelled
for viability and with HER2-Fc as described, followed
by surface-staining with anti-human IgG Fc-FITC
(BioLegend, 409,309), CD3ε-Alexa Fluor 700 at
10 μg/ml (BioLegend, 100,215) and CD8α-Brilliant
Violet 650 at 0.5 μg/ml (BioLegend, 100,741). To
stain for intracellular cytokines, cells were fixed and
permeabilized (Biolegend) according to the manufac-
turer protocol, before being stained with the anti-
bodies IFNγ-PerCP/Cy5.5 at 0.5 μg/ml (Biolegend,
505,821) and TNFα-Pacific Blue at 1 μg/ml (Biolegend,
506,318) diluted in permeabilization buffer (Biolegend) for
30 min on ice. Cells were finally washed twice in
permabilization buffer and resuspended in FACS buf-
fer prior to acquisition.
Fas and DR5 blockade
Human Fas-Fc was obtained from Adipogen
(AG-40B-0082-C050), and human DR5-Fc and control
IgG1-Fc portion was produced at the protein production
core facility at EPFL, Lausanne. Specificities of human
Fas-Fc and DR5-Fc for blocking their murine orthologs
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have been previously described [30, 31]. The biological ac-
tivity of DR5-Fc was compared to a reference sample
through its ability to inhibit TRAIL-mediated apoptosis of
Jurkat cells. BFP or CAR OT-1 T cells were transferred in
C57BL/6 mice, which were subsequently infected with
rLm-OVA as described previously. Based on the in vitro
testing, 200 μg of Fas-Fc and 500 μg of DR5-Fc or human
IgG1 control, were injected i.v. on days 4, 5 and 6
post-infection.
Statistical analyses
Statistical analyses were performed with Graphpad Prism
7. Normally distributed data that include two groups
were compared using Two-tailed unpaired T tests. Stat-
istical significance was reached with P < 0.05. Normally
distributed data with more than two groups were com-
pared using One-way or Two-way ANOVA tests. Multiple
comparisons were corrected using Tukey and Sidak tests,
respectively. Normality was tested with a Shapiro-Wilk
test. On the plots, data represent mean ± SD.
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